176 related articles for article (PubMed ID: 35332215)
1. Evaluation of 41 single nucleotide polymorphisms in canine diffuse large B-cell lymphomas using MassARRAY.
Sirivisoot S; Kasantikul T; Techangamsuwan S; Radtanakatikanon A; Chen K; Lin TY; Rungsipipat A
Sci Rep; 2022 Mar; 12(1):5120. PubMed ID: 35332215
[TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis of factors affecting clinical outcome following CHOP-based chemotherapy in dogs with primary nodal diffuse large B-cell lymphoma.
Childress MO; Ramos-Vara JA; Ruple A
Vet Comp Oncol; 2018 Mar; 16(1):E159-E168. PubMed ID: 29152834
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of Ki67 and its correlation with mitotic index in dogs with diffuse large B-cell lymphoma treated with 19-week CHOP-based protocol.
Sierra Matiz OR; Santilli J; Anai LA; Da Silva MCL; Sueiro FA; Sequeira JL; Magalhães LF; Magalhães GM; Tinucci Costa M; Calazans SG
J Vet Diagn Invest; 2018 Mar; 30(2):263-267. PubMed ID: 29192554
[TBL] [Abstract][Full Text] [Related]
4. BCL2 and MYC are expressed at high levels in canine diffuse large B-cell lymphoma but are not predictive for outcome in dogs treated with CHOP chemotherapy.
Curran KM; Schaffer PA; Frank CB; Lana SE; Hamil LE; Burton JH; Labadie J; Ehrhart EJ; Avery PR
Vet Comp Oncol; 2017 Dec; 15(4):1269-1279. PubMed ID: 27514648
[TBL] [Abstract][Full Text] [Related]
5. Are B-symptoms more reliable prognostic indicators than substage in canine nodal diffuse large B-cell lymphoma.
Škor O; Bicanová L; Wolfesberger B; Fuchs-Baumgartinger A; Ruetgen B; Štěrbová M; Schwendenwein I; Kleiter M
Vet Comp Oncol; 2021 Mar; 19(1):201-208. PubMed ID: 33136315
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of CD25 expression in dogs with a noninvasive diagnosis of B-cell lymphoma treated with CHOP chemotherapy.
Sheng R; Clarke D; Laver T; Meichner K; Northrup N; Tarigo J
Vet Comp Oncol; 2023 Mar; 21(1):28-35. PubMed ID: 36111442
[TBL] [Abstract][Full Text] [Related]
7. Response-based modification of CHOP chemotherapy for canine B-cell lymphoma.
Benjamin SE; Sorenmo KU; Krick EL; Salah P; Walsh KA; Weinstein NM; Keuler NS; Avery AC; Atherton MJ; Lenz JA
Vet Comp Oncol; 2021 Sep; 19(3):541-550. PubMed ID: 33729654
[TBL] [Abstract][Full Text] [Related]
8. Peripheral blood cell ratios as prognostic factors in canine diffuse large B-cell lymphoma treated with CHOP protocol.
Henriques J; Felisberto R; Constantino-Casas F; Cabeçadas J; Dobson J
Vet Comp Oncol; 2021 Jun; 19(2):242-252. PubMed ID: 33247533
[TBL] [Abstract][Full Text] [Related]
9. How gene polymorphisms can influence clinical response and toxicity following R-CHOP therapy in patients with diffuse large B cell lymphoma.
Falduto A; Cimino F; Speciale A; Musolino C; Gangemi S; Saija A; Allegra A
Blood Rev; 2017 Jul; 31(4):235-249. PubMed ID: 28262268
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms in cytokine genes as prognostic markers in diffuse large B cell lymphoma patients treated with (R)-CHOP.
Liu D; Wang Y; Dong M; Guan S; Wang Y; Sun H; Wu N; Li S; Bai J; Chen F; Sun D; Jin Y
Ann Hematol; 2017 Feb; 96(2):227-235. PubMed ID: 27822610
[TBL] [Abstract][Full Text] [Related]
11. CHOP chemotherapy for the treatment of canine multicentric T-cell lymphoma.
Rebhun RB; Kent MS; Borrofka SA; Frazier S; Skorupski K; Rodriguez CO
Vet Comp Oncol; 2011 Mar; 9(1):38-44. PubMed ID: 21303452
[TBL] [Abstract][Full Text] [Related]
12. FCGR3A 158V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma.
Liu F; Ding H; Jin X; Ding N; Deng L; He Y; Zhu J; Song Y
DNA Cell Biol; 2014 Sep; 33(9):616-23. PubMed ID: 25050883
[TBL] [Abstract][Full Text] [Related]
13. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
Akyurek N; Uner A; Benekli M; Barista I
Cancer; 2012 Sep; 118(17):4173-83. PubMed ID: 22213394
[TBL] [Abstract][Full Text] [Related]
15. Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone.
Wu PY; Zhang XD; Zhu J; Guo XY; Wang JF
Hum Pathol; 2014 Aug; 45(8):1664-73. PubMed ID: 24931464
[TBL] [Abstract][Full Text] [Related]
16. MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
Xu-Monette ZY; Møller MB; Tzankov A; Montes-Moreno S; Hu W; Manyam GC; Kristensen L; Fan L; Visco C; Dybkaer K; Chiu A; Tam W; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Wu L; Zhao X; Bueso-Ramos CE; Wang SA; Go RS; Li Y; Winter JN; Piris MA; Medeiros LJ; Young KH
Blood; 2013 Oct; 122(15):2630-40. PubMed ID: 23982177
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB
J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537
[TBL] [Abstract][Full Text] [Related]
19. Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program.
Li Y; Gordon MW; Xu-Monette ZY; Visco C; Tzankov A; Zou D; Qiu L; Montes-Moreno S; Dybkaer K; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huang Q; Ai W; Ponzoni M; Ferreri AJ; Winter JN; Go RS; Piris MA; Møller MB; Wu L; Wang M; Ramos KS; Medeiros LJ; Young KH
Blood; 2013 May; 121(22):4529-40. PubMed ID: 23515929
[TBL] [Abstract][Full Text] [Related]
20. ALDH1A1 mediates resistance of diffuse large B cell lymphoma to the CHOP regimen.
Song YH; Zhong MZ; Gan PP; Yi PY; Tang YH; Liu YP; Jiang JQ; Li L
Tumour Biol; 2014 Dec; 35(12):11809-17. PubMed ID: 25344211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
